Receveur, Jean-Marie; Murray, Anthony; Linget, Jean-Michel; Norregaard, Pia K.; Cooper, Martin; Bjurling, Emelie; Nielsen, Peter Aadal; Hoegberg, Thomas published the article 《Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier》. Keywords: CB1 receptor antagonist preparation pharmacokinetic structure activity lipophilicity; pyrazole carboxamide derivative preparation CB1 cannabinoid receptor antagonist.They researched the compound: 6-(Piperazin-1-yl)nicotinonitrile( cas:149554-29-0 ).Safety of 6-(Piperazin-1-yl)nicotinonitrile. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:149554-29-0) here.
A series of amides, amidines and amidoximes have been made from the corresponding nitrile compounds, to provide potent antagonists and inverse agonists for the CB1 receptor with considerably lower lipophilicity, higher polar surface area and improved plasma/brain ratios compared to the centrally acting rimonabant. Extensive investigations of ADME and in vivo pharmacol. properties led to selection of the amide series and specifically the 4-(4-fluorophenyl)piperidin-4-ol derivative D4. A clear improvement in the peripheral profile over rimonabant was seen, although some contribution of central effect on the pronounced weight reduction in obese mice cannot be ruled out.
From this literature《Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier》,we know some information about this compound(149554-29-0)Safety of 6-(Piperazin-1-yl)nicotinonitrile, but this is not all information, there are many literatures related to this compound(149554-29-0).
Reference:
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI